Page 13 - Medication Guide News Today

Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy.Data published in the Journal of Addition MedicineRICHMOND, Va., Sept. 26, 2023...

Subcutaneous EPKINLY™ is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two or more lines...

Media Release Subcutaneous EPKINLYTM is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory large B-cell lymphoma after two...

 Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur...

TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...

Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma ...

Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus...

 Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited...

NEW YORK--(BUSINESS WIRE)--Sep 19, 2023--

Labeling for Biosimilar and Interchangeable Biosimilar Products